Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response

Source: MDLinx, April 2020

Given that objective responses in 30% to 50% of patients suffering from metastatic melanoma is mediated by adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL), as per multiple, small phase 2 trials, so, researchers assessed long-term clinical outcomes, intent-to-treat analysis, predictors of response as well as toxicity profile in a large patient cohort. The ACT trial included 179 refractory melanoma patients. TIL were given in combination with high-dose bolus interleukin-2 after preconditioning with cyclophosphamide and fludarabine.